Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | RARA | P10276 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | CTSV | O60911 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL3590770 | 0.86 | MAOB (0.42) | MAOBMAOAPKMNOX1PARP15 | |
| SCHEMBL3583451 | 0.85 | MAOB (0.44) | MAOBMAOAPKMNOX1PARP10 | |
| SCHEMBL3274391 | 0.78 | PARP10 (0.52) | MAOBMAOANOX1MRGPRX4PARP15 | |
| SCHEMBL16621263 | 0.76 | NR4A2 (0.53) | PKMALOX5 | |
| SCHEMBL4318791 | 0.76 | PARP10 (0.53) | MAOBMAOANOX1MRGPRX4PARP15 | |
| Lithium SCHEMBL3274398 | 0.75 | PARP10 (0.52) | MAOBMAOANOX1MRGPRX4PARP15 | |
| SCHEMBL2997270 | 0.75 | MAOB (0.62) | MAOBMAOANOX1MRGPRX4PARP15 | |
| SCHEMBL24302655 | 0.75 | ALDH1A1 (0.40) | MAOBPKMPARP15PARP10ALOX5 | |
| Hydrochloric Acid SCHEMBL9015457 | 0.74 | MAOB (0.61) | MAOBMAOANOX1MRGPRX4PARP15 | |
| SCHEMBL4422282 | 0.74 | MAOB (0.78) | MAOBMAOAPARP15PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846950-B2 | Histamine H3 receptor inhibitors, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| EP-1805169-B1 | HISTAMINE H3 RECEPTOR INHIBITORS, THEIR PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20080015235-A1 | Histamine H3 Receptor Inhibitors, Preparation and Therapeutic Uses | JESUDASON CYNTHIA D | 2008-01-17 | — | — | US | disclosed |
| EP-1805169-A1 | HISTAMINE H3 RECEPTOR INHIBITORS, THEIR PREPARATION AND THERAPEUTIC USES | Eli Lilly and Company (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006044228-A1 | HISTAMINE H3 RECEPTOR INHIBITORS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015235-A1 | Histamine H3 Receptor Inhibitors, Preparation and Therapeutic Uses | HRH3, HRH4, HCRTR1 | MAOB 618/4885MAOA 832/4885PKM 2789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.